Synthesis and Anticancer Activity of Dimeric Polyether Ionophores.
Antineoplastic Agents
/ chemical synthesis
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Ethers
/ chemistry
Humans
Ionophores
/ chemical synthesis
Lasalocid
/ chemistry
Molecular Structure
Monensin
/ chemistry
Pentacyclic Triterpenes
/ chemistry
Polymerization
Pyrans
/ chemistry
Betulinic Acid
Huisgen 1,3-dipolar cycloaddition
SAR analysis
antiproliferative activity
betulinic acid
in vitro assay
multi-drug resistance
polyether ionophores
stereoselective reactions
tumor-specificity
‘click’ chemistry
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
12 07 2020
12 07 2020
Historique:
received:
08
06
2020
revised:
09
07
2020
accepted:
10
07
2020
entrez:
16
7
2020
pubmed:
16
7
2020
medline:
17
4
2021
Statut:
epublish
Résumé
Polyether ionophores represent a group of natural lipid-soluble biomolecules with a broad spectrum of bioactivity, ranging from antibacterial to anticancer activity. Three seem to be particularly interesting in this context, namely lasalocid acid, monensin, and salinomycin, as they are able to selectively target cancer cells of various origin including cancer stem cells. Due to their potent biological activity and abundant availability, some research groups around the world have successfully followed semi-synthetic approaches to generate original derivatives of ionophores. However, a definitely less explored avenue is the synthesis and functional evaluation of their multivalent structures. Thus, in this paper, we describe the synthetic access to a series of original homo- and heterodimers of polyether ionophores, in which (i) two salinomycin molecules are joined through triazole linkers, or (ii) salinomycin is combined with lasalocid acid, monensin, or betulinic acid partners to form 'mixed' dimeric structures. Of note, all 11 products were tested in vitro for their antiproliferative activity against a panel of six cancer cell lines including the doxorubicin resistant colon adenocarcinoma LoVo/DX cell line; five dimers (
Identifiants
pubmed: 32664671
pii: biom10071039
doi: 10.3390/biom10071039
pmc: PMC7408349
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Ethers
0
Ionophores
0
Pentacyclic Triterpenes
0
Pyrans
0
salinomycin
62UXS86T64
Monensin
906O0YJ6ZP
Lasalocid
W7V2ZZ2FWB
Betulinic Acid
4G6A18707N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Narodowe Centrum Nauki
ID : 2016/23/D/ST5/00242
Pays : International
Organisme : Narodowe Centrum Nauki
ID : 2019/32/U/ST4/00092
Pays : International
Organisme : Narodowa Agencja Wymiany Akademickiej
ID : PPN/BEK/2019/1/00034
Pays : International
Références
Mol Cancer Ther. 2010 Dec;9(12):3175-85
pubmed: 21159605
Chem Biol Drug Des. 2015 Dec;86(6):1378-86
pubmed: 26058448
Bioorg Med Chem Lett. 2014 Nov 15;24(22):5190-4
pubmed: 25442310
Eur J Med Chem. 2018 Mar 25;148:279-290
pubmed: 29466777
PLoS One. 2014 Sep 03;9(9):e106186
pubmed: 25184280
Eur J Med Chem. 2017 Feb 15;127:900-908
pubmed: 27876192
Eur J Med Chem. 2018 Aug 5;156:510-523
pubmed: 30025346
Nat Chem. 2017 Oct;9(10):1025-1033
pubmed: 28937680
Bioorg Med Chem Lett. 2015 Oct 15;25(20):4539-43
pubmed: 26338363
Eur J Med Chem. 2019 Jul 1;173:90-98
pubmed: 30986574
Eur J Med Chem. 2019 Mar 15;166:32-47
pubmed: 30684869
Eur J Med Chem. 2014 Apr 9;76:435-44
pubmed: 24602789
Eur J Med Chem. 2015 Mar 26;93:33-41
pubmed: 25644674
Chem Biol Drug Des. 2019 Oct;94(4):1859-1864
pubmed: 31260603
Pharmacol Rev. 2004 Mar;56(1):53-102
pubmed: 15001663
Chemistry. 2017 Feb 10;23(9):2077-2083
pubmed: 27740704
Cell. 2009 Aug 21;138(4):645-659
pubmed: 19682730
Sci Rep. 2018 Dec 17;8(1):17914
pubmed: 30559409
Bioorg Med Chem Lett. 2017 Apr 1;27(7):1624-1626
pubmed: 28262526
Eur J Med Chem. 2019 Aug 15;176:208-227
pubmed: 31103901
J Biomed Biotechnol. 2012;2012:950658
pubmed: 23251084
Eur J Med Chem. 2019 Feb 15;164:366-377
pubmed: 30611056
Mol Nutr Food Res. 2009 Jan;53(1):140-6
pubmed: 19065582
Chem Commun (Camb). 2016 Apr 14;52(29):5136-9
pubmed: 26997457
Br J Haematol. 2002 Nov;119(2):400-7
pubmed: 12406077
Bioorg Med Chem Lett. 2013 Sep 15;23(18):5053-6
pubmed: 23932361
Anticancer Drugs. 2010 Mar;21(3):215-27
pubmed: 20075711
Expert Opin Drug Discov. 2009 Feb;4(2):109-46
pubmed: 23480512
Bioorg Med Chem Lett. 2014 Apr 1;24(7):1724-9
pubmed: 24631190
Chem Commun (Camb). 2013 Nov 4;49(85):9944-6
pubmed: 24037337
Biomed Pharmacother. 2017 Apr;88:1016-1024
pubmed: 28178613
Sci Rep. 2019 Feb 4;9(1):1200
pubmed: 30718715
Chemistry. 2020 Jun 10;26(33):7416-7424
pubmed: 32083773
Chem Biol Drug Des. 2015 Oct;86(4):911-7
pubmed: 25607278
Eur J Med Chem. 2019 Mar 15;166:48-64
pubmed: 30684870
Biomed Res Int. 2013;2013:162513
pubmed: 23586016
Bioorg Med Chem Lett. 2020 May 1;30(9):127062
pubmed: 32147358